<strong><span style="font-family: TimesNewRomanPS-BoldMT;"><font face="TimesNewRomanPS-BoldMT"><p align="left"> </p></font></span><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">ABSTRACT</span></span></p></strong><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">In the first part of this article, drug utilization and prescribing practice is discussed as seen from a</p><p align="left">Norwegian general practice perspective. Which are the data sources available? What kind of studies</p><p align="left">have been performed? Prescription-diagnosis studies are reviewed, in particular the Møre & Romsdal</p><p align="left">Prescription Study (MRPS). Because the wholesales drug statistics do not include information about</p><p align="left">neither patients, prescribers or diagnoses, there is a current need for establishing a more comprehensive</p><p align="left">statistics giving wider and deeper insights into the prescribing and utilization of drugs in the Norwegian</p><p align="left">society. The proposed Norwegian prescription statistics is discussed in relation to previous experiences</p><p align="left">from prescription-diagnosis studies and current needs for research and statistics in the field. Some</p><p align="left">examples are given illustrating why the 11-digit person number probably should be included in the</p><p align="left">database. Lack of diagnostic information may to some extent be compensated for by introducing a more</p><p align="left">differentiated list of diagnoses for the drugs reimbursed. The use of data from this statistics for quality</p><p align="left">assurance in e.g. general practice is discussed. Finally, some suggestions are given for how the Norwegian</p><p>prescription statistics may be organised.</p></span></span>